GPIIb/IIIa inhibitors: From bench to bedside and back to bench again

Summary

From the discovery of the platelet glycoprotein (GP) IIb/IIIa and identification of its central role in haemostasis, the integrin GPIIb/IIIa (αIIbβ3, CD41/CD61) was destined to be an anti-thrombotic target. The subsequent successful development of intravenous ligand-mimetic inhibitors occurred during a time of limited understanding of integrin physiology. Although efficient inhibitors of ligand binding, they also mimic ligand function. In the case of GPIIb/IIIa inhibitors, despite strongly inhibiting platelet aggregation, paradoxical fibrinogen binding and platelet activation can occur. The quick progression to development of small-molecule orally available inhibitors meant that this approach inherited many potential flaws, which together with a short half-life resulted in an increase in mortality and a halt to the numerous pharmaceutical development programs. Limited clinical benefits, together with the success of other anti-thrombotic drugs, in particular P₂Y₁₂ ADP receptor blockers, have also led to a restrictive use of intravenous GPIIb/ IIIa inhibitors. However, with a greater understanding of this key platelet-specific integrin, GPIIb/IIIa remains a potentially attractive target and future drug developments will be better informed by the lessons learnt from taking the current inhibitors back to the bench. This overview will review the physiology behind the inherent problems of a ligand-based integrin inhibitor design and discuss novel promising approaches for GPIIb/IIIa inhibition.

Keywords

GP IIb/IIIa - platelet pharmacology - antiplatelet agents - thrombosis

• References

• 1 Nurden AT. et al. Platelet membrane glycoproteins: historical perspectives. J Thromb Haemost 2006; 04: 3-9.
• 2 Wagner C. et al. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907-914.
• 3 Quinn M. et al. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Circulation 1999; 99: 2231-2238.
• 4 Duperray A. et al. Biosynthesis and assembly of platelet GPIIb-IIIa in human megakaryocytes: evidence that assembly between pro-GPIIb and GPIIIa is a prerequisite for expression of the complex on the cell surface. Blood 1989; 74: 1603-1611.
• 5 Thornton MA. et al. The Human Platelet αIIb Gene Is Not Closely Linked to Its Integrin Partner β3. Blood 1999; 94: 2039-2047.
• 6 Xiong JP. et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002; 296: 151-155.
• 7 Xiao T. et al. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 59-67.
• 8 Calvete JJ. Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost 1994; 72: 1-15.
• 9 Phillips DR. et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-843.
• 10 Weisel JW. et al. Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 1992; 267: 16637-16643.
• 11 Farrell DH. et al. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci USA 1992; 89: 10729-10732.
• 12 Zhu J. et al. Closed headpiece of integrin alphaIIbbeta3 and its complex with an alphaIIbbeta3-specific antagonist that does not induce opening. Blood 2010; 116: 5050-5059.
• 13 Ma YQ. et al. Platelet integrin αIIbβ3: activation mechanisms. J Thromb Haemost 2007; 05: 1345-1352.
• 14 Ye F. et al. Molecular mechanism of inside-out integrin regulation. J Thromb Haemost 2011; 09 (Suppl. 01) 20-25.
• 15 Petrich BG. Talin-dependent integrin signalling in vivo. Thromb Haemost 2009; 101: 1020-1024.
• 16 Stefanini L, Bergmeier W. CalDAG-GEFI and platelet activation. Platelets 2010; 21: 239-243.
• 17 Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008; 112: 3011-3025.
• 18 Arias-Salgado EG. et al. Src kinase activation by direct interaction with the integrin β cytoplasmic domain. Proc Natl Acad Sci 2003; 100: 13298-13302.
• 19 Flevaris P. et al. A molecular switch that controls cell spreading and retraction. J Cell Biol 2007; 179: 553-565.
• 20 Soriani A. et al. A role for PKC theta in outside-in alpha(IIb)beta(3) signaling. J Thromb Haemost 2006; 04: 648-655.
• 21 Elvers M. et al. Impaired alpha(IIb)beta(3) integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1. Sci Signal. 2010 03. ra1.
• 22 Prevost N. et al. Group I VA cytosolic phospholipase A(2) (cPLA(2)alpha) and integrin alpha IIb beta 3 reinforce each other's functions during alpha IIb beta 3 signaling in platelets. Blood 2009; 113: 447-457.
• 23 Schoenwaelder SM. et al. Identification of a unique co-operative phosphoinositide 3-kinase signaling mechanism regulating integrin alpha(IIb)beta(3) adhesive function in platelets. J Biol Chem 2007; 282: 28648-28658.
• 24 Gong H. et al. G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin “outside-in” signaling. Science 2010; 327: 340-343.
• 25 Zhu J. et al. Tests of the extension and deadbolt models of integrin activation. J Biol Chem 2007; 282: 11914-11920.
• 26 Gao C. et al. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. J Clin Invest 2009; 119: 504-511.
• 27 Jennings LK. et al. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost 2000; 84: 1095-1102.
• 28 Zhu J. et al. Requirement of alpha and beta subunit transmembrane helix separation for integrin outside-in signaling. Blood 2007; 110: 2475-2483.
• 29 Peter K. et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998; 92: 3240-3249.
• 30 Knight DM. et al. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immun 1995; 32: 1271-1281.
• 31 Topol EJ. et al. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-231.
• 32 Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997; 80: 11B-20B.
• 33 Egbertson MS. et al. Non-peptide fibrinogen receptor antagonists. optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 1994; 37: 2537-2551.
• 34 Lefkovits J. et al. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559.
• 35 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994 330. 956-961.
• 36 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997 336. 1689-1697.
• 37 The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997 349. 1422-1428.
• 38 The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000 356. 2037-2044.
• 39 Theroux P. et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation 2000; 102: 2466-2472.
• 40 Mehilli J. et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110: 3627-3635.
• 41 Schuhlen H. et al. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. Am Heart J 2006; 151: 1248-1254.
• 42 Steg PG. et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854-1864.
• 43 Mehilli J. et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 2009; 119: 1933-1940.
• 44 Valgimigli M. et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009; 119: 3215-3222.
• 45 Berkowitz SD. et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998; 32: 311-319.
• 46 Aster RH. et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost 2006; 04: 678-679.
• 47 Manoukian SV. The relationship between bleeding and adverse outcomes in ACS and PCI: pharmacologic and nonpharmacologic modification of risk. J Invasive Cardiol 2010; 22: 132-141.
• 48 Kim YH. et al. Impact of bleeding on subsequent early and late mortality after drug-eluting stent implantation. JACC Cardiovasc Interv 2011; 04: 423-431.
• 49 Starnes HB. et al. Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions. Drugs 2011; 71: 2009-2030.
• 50 Brener SJ. et al. The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial. Am Heart J 2005; 150: 89-93.
• 51 Sinnaeve PR. et al. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. Am Heart J 2004; 147: 993-998.
• 52 Cox D. Oral GPIIb/IIIa antagonists: what went wrong?. Curr Pharm Des 2004; 10: 1587-1596.
• 53 Chew DP. et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201-206.
• 54 Cox D. et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1514-1519.
• 55 Holmes MB. et al. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. Am J Cardiol. 2000 85. 491-493. A10.
• 56 The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet. 2000 355. 337-345.
• 57 O'Neill WW. et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000; 342: 1316-1324.
• 58 Kristensen S. et al. Contemporary use of glycoprotein IIb/IIIa inhibitors. Thromb Haemost 2012; 107: 215-224.
• 59 Lip GY. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
• 60 Winchester DE. et al. Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization: A Meta-Analysis of Randomized Trials Performed in the Era of Stents and Thienopyridines. J Am Coll Cardiol 2011; 57: 1190-1199.
• 61 Artoni A. et al. Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci USA 2004; 101: 13114-13120.
• 62 Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687.
• 63 Du XP. et al. Ligands “activate” integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell 1991; 65: 409-416.
• 64 Bassler N. et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. Arterioscler Thromb Vasc Biol 2007; 27: e9-15.
• 65 Peter K. et al. Intrinsic activating properties of GP IIb/IIIa blockers. Thromb Res 2001; 103 (Suppl. 01) S21-27.
• 66 Cox D. et al. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010; 09: 804-820.
• 67 Jones ML. et al. RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation. J Thromb Haemost 2010; 08: 567-576.
• 68 Attaya S. et al. Acute profound thrombocytopenia with second exposure to eptifibatide associated with a strong antibody reaction. Platelets 2009; 20: 64-67.
• 69 Peter K. et al. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 1999; 84: 519-524.
• 70 Bednar B. et al. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 1999; 94: 587-599.
• 71 Schwarz M. et al. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J 2004; 18: 1704-1706.
• 72 Hantgan RR, Stahle MC. Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3: PAC-1 molecular recognition. Biochemistry 2009; 48: 8355-8365.
• 73 Hantgan RR. et al. αIIbβ3 priming and clustering by orally active and intravenous integrin antagonists. J Thromb Haemost 2007; 05: 542-550.
• 74 Reynolds AR. et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009; 15: 392-400.
• 75 Lele M. et al. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 2001; 104: 582-587.
• 76 Schwarz M. et al. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2). Thromb Res 2002; 107: 121-128.
• 77 Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001; 86: 427-443.
• 78 Peter K. et al. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. Circulation 2000; 102: 1490-1496.
• 79 Schwarz M. et al. Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther 2004; 308: 1002-1011.
• 80 Moliterno DJ. et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002; 360: 355-360.
• 81 Van't Hof AW. et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multi-centre, double-blind, randomised controlled trial. Lancet 2008; 372: 537-546.
• 82 Huber K. et al. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J 2010; 31: 1708-1716.
• 83 Blue R. et al. Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist. Blood 2009; 114: 195-201.
• 84 Blue R. et al. Application of high-throughput screening to identify a novel αIIb-specific small- molecule inhibitor of αIIbβ3-mediated platelet interaction with fibrinogen. Blood 2008; 111: 1248-1256.
• 85 Schwarz M. et al. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 2006; 99: 25-33.
• 86 Hagemeyer CE. et al. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost 2009; 101: 1012-1019.
• 87 Stoll P. et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol 2007; 27: 1206-1212.
• 88 Topcic D. et al. An activation-specific platelet inhibitor that can be turned on/off by medically used hypothermia. Arterioscler Thromb Vasc Biol 2011; 31: 2015-2023.
• 89 Weitz-Schmidt G. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 07: 687-692.
• 90 Ahrens I, Peter K. Therapeutic integrin inhibition: allosteric and activation-specific inhibition strategies may surpass the initial ligand-mimetic strategies. Thromb Haemost 2008; 99: 803-804.
• 91 Haas TA. Allosteric regulation of alpha(IIb)beta(3) by beta(3) 95–105. Thromb Haemost 2008; 99: 701-710.